Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and dA Story by MedicilonRecently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration. The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapRecently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration. The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapy. Since its establishment in 2015, EyeCure has been deeply involved in the field of ophthalmic cell and gene therapy. Its research and development focus on the development of human retinal pigment epithelial cells, corneal cells and mesenchymal stem cells, creating a new therapeutic field of using adult RPE cells to treat age-related macular degeneration and pigmentary degeneration. Medicilon, as a one-stop preclinical biopharmaceutical comprehensive R&D service CRO, has also been deeply involved in the field of ophthalmic drugs for many years, and has established the "Medicilon Preclinical Ophthalmic Drug Research Platform" which can provide efficient, high-quality, and cost-effective drug discovery, pharmaceutical research, preclinical research services. Medicilon Preclinical Ophthalmic Drug Development Platform |
Stats
39 Views
Added on July 18, 2023 Last Updated on July 18, 2023 Tags: drug discovery, pharmaceutical research, preclinical research, ophthalmology drug AuthorMedicilonCambridge, MAAboutMedicilon is an integrated contract research organization (CRO), providing comprehensive one-stop new drug R&D services for pharmaceutical enterprises and scientific research institutions around the w.. more..Writing
|